Abstract
Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this subgroup. This article has reviewed the main articles that have analyzed these items.
Keywords: Adjuvant Online, aging, anit-HER2 therapy, breast cancer, cardiotoxicity, chemotherapy, comorbidity, Comprehensive Geriatric Assessment, elderly women, histology, HER2 positive, lapatinib, St Gallen criteria, targeted therapy, trastuzumab.
Anti-Cancer Agents in Medicinal Chemistry
Title:Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
Volume: 14 Issue: 5
Author(s): M.J. Molina-Garrido, C. Guillen-Ponce and A. Mora-Rufete
Affiliation:
Keywords: Adjuvant Online, aging, anit-HER2 therapy, breast cancer, cardiotoxicity, chemotherapy, comorbidity, Comprehensive Geriatric Assessment, elderly women, histology, HER2 positive, lapatinib, St Gallen criteria, targeted therapy, trastuzumab.
Abstract: Trastuzumab or lapatinib treatment with chemotherapy or hormonotherapy are the gold standard treatments for human epidermal growth factor receptor 2 (HER2)-positive breast cancer (early breast cancer or metastatic breast cancer). Older patients have been largely underrepresented in clinical trials, and few data on trastuzumab or lapatinib efficacy and toxicity have been reported for this subgroup. This article has reviewed the main articles that have analyzed these items.
Export Options
About this article
Cite this article as:
Molina-Garrido M.J., Guillen-Ponce C. and Mora-Rufete A., Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (5) . https://dx.doi.org/10.2174/18715206113139990087
DOI https://dx.doi.org/10.2174/18715206113139990087 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics Meet Our Editorial Board Member
Letters in Drug Design & Discovery Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy Choosing between Targeted Therapies for Rheumatoid Arthritis Patients: The Oncology Perspective
Current Rheumatology Reviews Structural and Modeling Studies on ecto-5’-nucleotidase Aiding in Inhibitor Design
Mini-Reviews in Medicinal Chemistry Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets A Comprehensive Review on SAR of Curcumin
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: New Approaches to Treating Cancer: Medicinal Chemistry and Therapeutic Potential (Guest Editor: David J. Weber)]
Current Topics in Medicinal Chemistry Hijacking the Hedgehog Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Commentary Research Highlights: Adaptive PTEN Loss Enhances the Outgrowth of Brain Metastatic Tumour Cells
CNS & Neurological Disorders - Drug Targets Anti-carcinogenic Effect of Cathepsin K Inhibitor, Odanacatib with a Low Dose of Cisplatin Against Human Breast Carcinoma MCF-7 and MDA-MB231 Cells
Current Cancer Therapy Reviews Xenobiotic and Non-Xenobiotic Interventions in the Microbiome Therapeutics
Current Drug Metabolism Characteristic Alterations of Nuclear Structure and Chromatin Organisation of Cancer Cells Addressed by Proteome Analysis**
Current Proteomics Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Editorial
Current Medical Imaging Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Monoclonal Antibodies in Solid Tumours
Current Clinical Pharmacology Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Bisphosphonates in the Prevention of Disease Recurrence: Current Results and Ongoing Trials
Current Cancer Drug Targets